Analysis of NUP98/NSD1 translocations in adult AML and MDS patients

Leukemia

Volumn 27, Issue 3, 2013, Pages 750-754

  Thol, F ^a   Kolking B ^a   Hollink, I H I ^b   Damm, F ^a   Van Den Heuvel Eibrink, M M ^b   Michel Zwaan, C ^b   Bug, G ^c   Ottmann, O ^c   Wagner, K ^a   Morgan, M ^a   Hofmann, W K ^d   Gohring G ^a   Schlegelberger, B ^a   Krauter, J ^a   Ganser, A ^a   Heuser, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR RECEPTOR BINDING SET DOMAIN PROTEIN 1; NUCLEOPORIN 98; PROTEIN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME ABERRATION; CYTOGENETICS; GENE MUTATION; GENE TRANSLOCATION; HUMAN; LETTER; LEUKOCYTE COUNT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; COHORT STUDIES; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PORE COMPLEX PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; SURVIVAL RATE; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84875225956     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.249     Document Type: Letter

References (15)

1. Gough SM, Slape CI, Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood 2011; 118: 6247-6257.
2. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011; 118: 3645-3656.
3. Qiao Q, Li Y, Chen Z, Wang M, Reinberg D, Xu RM. The structure of NSD1 reveals an autoregulatory mechanism underlying histone H3K36 methylation. J Biol Chem 2011; 286: 8361-8368.
4. Heil G, Krauter J, Raghavachar A, Bergmann L, Hoelzer D, Fiedler W et al. Riskadapted induction and consolidation therapy in adults with de novo AML aged o/1/2 60 years: results of a prospective multicenter trial. Ann Hematol 2004; 83: 336-344.
5. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499-2506.
6. Thol F, Damm F, Lü deking A, Winschel C, Wagner K, Morgan M et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011; 29: 2889-2896.
7. Damm F, Oberacker T, Thol F, Surdziel E, Wagner K, Chaturvedi A et al. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J Clin Oncol 2011; 29: 682-689.
8. Thol F, Kade S, Schlarmann C, Loffeld P, Morgan M, Krauter J et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119: 3578-3584.
9. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
10. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med 1986; 5: 255-260.
11. Yamamoto K, Nakamachi Y, Yakushijin K, Funakoshi Y, Okamura A, Kawano S et al. Expression of the novel NUP98/PSIP1 fusion transcripts in myelodysplastic syndrome with t(9;11)(p22;p15). Eur J Haematol 2012; 88: 244-248.
12. Taketani T, Taki T, Nakamura H, Taniwaki M, Masuda J, Hayashi Y. NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes. Cancer Genet Cytogenet 2009; 190: 108-112.
13. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002; 39(Suppl 3): 6-11.
14. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol 2007; 9: 804-812.
15. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.